upon further reading,

As at September 30, 2012, the Company had a contingent obligation to Orrick, Herrington and Sutcliffe LLP, lead legal counsel for the lawsuit against Alnylam and AlCana of $15,887,877). As a result of the settlement of the litigation between Tekmira and Alnylam plus costs incurred after September 30, 2012, are now payable to Orrick and will be recorded in Q4 2012.

So that would reduce their Cash per share  to about $4.00  --- so maybe a little bit more downside --- but stil they are flush with cash until end of 2015 to complete their clinical trial and development.

I want to buy more -- but the overall Market is too bearish.